Key Takeaways Recent clinical trials have established glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a major breakthrough in the management of nonalcoholic steatohepatitis (NASH)
But new research is raising a troubling safety question: could semaglutidethe active ingredient in several of these drugscause serious vision damage
Histological observation After the experiment, lesional skin samples (treated with different formulations) and organs (heart, liver, spleen, lungs, kidneys) were fixed in 4% paraformaldehyde (Servicebio, G1101)
According to a study in a well-known medical journal, when adults who were overweight or obese (but didnt have diabetes) took semaglutide along with making lifestyle changes, they experienced significant and lasting weight loss
Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk